SIGA TECHNOLOGIES INC (SIGA)
Health Care · Biodefense pharmaceuticals / orthopoxvirus antivirals · NASDAQ
SIGA is a biodefense-focused pharmaceutical company selling tecovirimat (TPOXX®), an FDA-approved smallpox antiviral, primarily to the U.S. Strategic National Stockpile and international governments.
What SIGA TECHNOLOGIES INC does
SIGA Technologies is a commercial-stage pharmaceutical company that develops and sells TPOXX® (tecovirimat), an antiviral drug for treating human smallpox and other orthopoxviruses. The company produces both oral and intravenous formulations of TPOXX®, with sales primarily to the U.S. Government's Strategic National Stockpile and international governments. TPOXX® is FDA-approved for smallpox treatment and has received regulatory approval from the EMA, Health Canada, MHRA (UK), and PMDA (Japan) for smallpox, monkeypox, cowpox, and vaccinia complications.
Themes: ["Smallpox / orthopoxvirus antivirals","Monkeypox (mpox) treatment","Biodefense / Strategic National Stockpile","Rare disease / orphan drug","Government procurement"]
Fundamentals
- Price$3.50 as of 2026-07-09 close
- Market cap$247M as of 2026-07-10
- 1-year return-47.7% as of 2026-07-09 close
- P/E12.19 as of 2026-07-10
- Net margin+21.6% as of 2026-07-10
- Gross margin+65.4% as of 2026-07-10
- ROE+10.6% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)-22.1% as of 2026-07-10
- Revenue CAGR (3y)-5.1% SEC XBRL
- Beta0.91 as of 2026-07-10
Dividend: yield +17.5%; 4-year non-decreasing per-share dividend streak (SEC XBRL).
Key risks (from latest filing)
["Regulatory uncertainty: EMA's Committee for Medicinal Products for Human Use (CHMP) initiated a referral procedure in July 2025 questioning the effectiveness of Tecovirimat-SIGA for mpox treatment, with potential for withdrawal of the mpox indication and potential suspension or withdrawal of the overall marketing authorization.","Revenue concentration and dependency: The company's sales are primarily concentrated to U.S. and international governments through procurement contracts, creating dependency on government demand and budget allocation for Strategic Stockpile acquisitions.","Macroeconomic and supply chain risk: Tariffs and trade policy volatility could materially increase manufacturing costs, particularly for IV TPOXX® which relies on European raw materials, adversely impacting operating results."]
Competitors & peers
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.